title: P63 expression in conjunctival proliferative diseases: pterygium and laryngo-onycho-cutaneous (LOC) syndrome.
abstract: OBJECTIVE
  Compare expression of p63 in pterygium and laryngo-onycho-cutaneous (LOC) syndrome with normal conjunctiva.
  
  
  METHODS
  P63 immunohistochemical detection was carried out in normal, pterygium, and LOC conjunctival tissue. In vitro, growth of normal conjunctival biopsy specimens, pterygium, and LOC in growth tissue was compared.
  
  
  RESULTS
  In normal conjunctiva, p63 was poorly expressed in the infranasal quadrant, with 36% of cells stained vs. 55 to 59% in other quadrants (p < 0.05). In pterygium, p63 was overexpressed (59% cells stained) compared to normal supranasal (55%) and normal infranasal conjunctiva (36%, p < 0.05). In LOC, p63 was only expressed in 39% of cells vs. 58% in normal supratemporal conjunctiva (p < 0.05). Cytokeratin 19 was expressed by all cells cultured from normal conjunctival tissue.
  
  
  CONCLUSIONS
  This study emphasizes the importance of using control tissue explanted from the correspondent conjunctival quadrant when studying proliferative disorders. Different pathogenesis may account for the differences in p63 expression between pterygium and LOC.
authors.affiliation: Centre for Molecular Biosciences, School of Biomedical Sciences, Coleraine, Northern Ireland.
authors.forename: Sarah D
authors.initials: SD
authors.lastname: Atkinson
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Moore
authors.forename: Sunil
authors.initials: S
authors.lastname: Shah
authors.forename: Anant
authors.initials: A
authors.lastname: Sharma
authors.forename: Richard M
authors.initials: RM
authors.lastname: Best
authors.forename: Antonio
authors.initials: A
authors.lastname: Leccisotti
authors.forename: Mohammad
authors.initials: M
authors.lastname: Alarbi
authors.forename: David
authors.initials: D
authors.lastname: Rimmer
authors.forename: Tom
authors.initials: T
authors.lastname: Gardiner
authors.forename: Tara C B
authors.initials: TC
authors.lastname: Moore
mesh_terms: D018929:Cell Culture Techniques; D003228:Conjunctiva / Q000166:cytology / Q000378:metabolism*; D003229:Conjunctival Diseases / Q000378:metabolism* / Q000473:pathology; D004820:Epidermolysis Bullosa / Q000378:metabolism* / Q000473:pathology; D006097:Granulation Tissue / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D007818:Laryngeal Diseases / Q000378:metabolism* / Q000473:pathology; D011625:Pterygium / Q000378:metabolism* / Q000473:pathology; D013577:Syndrome; D015534:Trans-Activators / Q000378:metabolism*; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins